Dr. Ferrans stated, "Today, adult stem cells are used to successfully treat advanced forms of cancer through the process of bone marrow transplantation. I am very excited about the very promising future of adult stem cell therapy. Numerous peer reviewed clinical trials have clearly demonstrated the potential for adult stem cell therapy to have enormous impact on the treatment of coronary artery disease, congestive heart failure, new onset diabetes, and a number of other neurologic, auto-immune, and musculoskeletal disorders. Stem Cell Assurance will help bring a broad array of consumer oriented services related to adult stem cells to help those seeking healthier lives."
Richard Ferrans, M.D. is the Chairman of Stem Cell Assurance and brings over 10 years experience as a physician leader in biotech, medical informatics, and care systems. Dr. Ferrans is the former Chief of Medical Informatics for LSU Health Sciences Center and Assistant Professor of Public Health and Clinical Assistant Professor of Medicine. He has been served as President and Founder of Avreo Inc., and Senior VP of Labnetics (now DxTech). He has also been a medical director of a large Medicare Advantage Plan, and the CMIO of a not-for-profit community hospital. Dr. Ferrans is a former staff member of the National Committee for Vital and Health Statistics, and has testified before the FDA and the U.S. Senate of policy and regulatory issues surrounding medical biotechnology and medical technology. Dr.
Ferrans is currently enrolled in the Harvard School of Public Health Masters in Healthcare Management Program.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.
SOURCE Traxxec Ltd

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index